Management of invasive candidiasis in the intensive care unit

Drugs

Volumn 70, Issue 7, 2010, Pages 823-839

  Playford, E Geoffrey ^a,b   Lipman, Jeff ^b,c   Sorrell, Tania C ^d,e  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Amphotericin B liposomal, therapeutic use; Anidulafungin, therapeutic use; Candidaemia, treatment; Candidiasis, treatment; Caspofungin, therapeutic use; Fluconazole, therapeutic use; Intensive care units; Micafungin, therapeutic use; Research and development

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; DIAGNOSTIC VALUE; ECONOMIC ASPECT; FUNGUS CULTURE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTENSIVE CARE UNITS;

CANDIDA; CANDIDA GLABRATA;

EID: 77951724037     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10898550-000000000-00000     Document Type: Review

References (166)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20 (6): 1526-1530
2. Beck-Sague C, Jarvis WR. Secular trends in the epide-miology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167 (5): 1247-1251
3. Ostrosky-Zeichner L. New approaches to the risk of Can-dida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-537
4. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38 (3): 311-320
5. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect 2005; 11 (11): 908-913
6. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-244
7. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27 (5): 887-892
8. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21 (8): 510-515
9. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. Na-tional epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29 (2): 253-258
10. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study [published erratum appears in Clin Infect Dis 2004 Oct 1; 39 (7): 1093]. Clin Infect Dis 2004; 39 (3): 309-317
11. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candide-mia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23 (1): 23-30
12. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32 Suppl. 2: S87-91
13. Marriott DJE, Playford EG, Chen S, et al. Determinants of mortality in non-neutropenic ICU patients with candi-daemia. Crit Care 2009; 13 (4): R115
14. Laupland KB, Zygun DA, Davies HD, et al. Population-based assessment of intensive care unit-acquired bloodstream infections in adults: incidence, risk factors, and associated mortality rate. Crit Care Med 2002; 30 (11): 2462-2467
15. Blot SI, Depuydt P, Annemans L, et al. Clinical and eco-nomic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005; 41 (11): 1591-1598
16. Spencer RC. Predominant pathogens found in the Europ-ean prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996; 15: 281-285
17. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-1200
18. Pfaller MA, Diekema DJ. Epidemiology of invasive can-didiasis: a persistent public health problem. Clin Micro-biol Rev 2007; 20 (1): 133-163
19. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3 (11): 685-702
20. Ostrosky-Zeichner L, Pappas P. Invasive candidasis in the intensive care unit. Crit Care Med 2006; 34 (3): 857-863
21. Bougnoux M-E, Kac G, Aegerter P, et al., CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008; 34 (2): 292-299
22. Yap HY, Kwok KM, Gomersall CD, et al. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med 2009; 15 (4): 255-261
23. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989: National Nosocomial Infections Surveillance System. Am J Med 1991; 91 (3B): 86S-9S
24. Voss A, Kluytmans JA, Koeleman JG, et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996; 15 (12): 909-912
25. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. In-creasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40 (9): 3489-3492
26. Poikonen E, Lyytikainen O, Anttila V-J, et al. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9 (8): 985-990
27. Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): results from a Nationwide Study. J Clin Microbiol 2006; 44 (6): 1977-1981
28. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35 (5): 627-630
29. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42 (4): 1519-1527
30. Laupland KB, Gregson DB, Church DL, et al. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005; 56 (3): 532-537
31. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14 (5): 487-494
32. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008; 29 (10): 978-980
33. Playford EG, Nimmo GR, Tilse M, et al. The increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect. In Press
34. Leroy O, Gangneux J-P, Montravers P, et al. Epidemiol-ogy, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37 (5): 1612-1618
35. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50 (4): 302-310
36. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36 (7): 2034-2039
37. Gleason TG, May AK, Caparelli D, et al. Emerging evi-dence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997; 132 (11): 1197-1201
38. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in anti-fungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37 (3): 531-537
39. Bassetti M, Ansaldi F, Nicolini L, et al. Incidence of can-didaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009; 64 (3): 625-629
40. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21
41. Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006; 58 (2): 474-477
42. Magill SS, Swoboda SM, Shields CE, et al. The epide-miology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg 2009; 249 (4): 657-665
43. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29: 2162-2169
44. Parkins MD, Sabuda DM, Elsayed S, et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60 (3): 613-618
45. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645
46. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34 (3): 646-652
47. Blot S, Dimopoulos G, Rello J, et al. Is Candida really a threat in the ICU? Curr Opin Crit Care 2008; 14 (5): 600-604
48. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of no-socomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-485
49. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in in-tensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17 (3): 168-175
50. Pelz RK, Lipsett PA, Swoboda SM, et al. Candida infec-tions: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000; 15: 255-261
51. Rentz AM, Halpern MT, Bowden R. The impact of can-didemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-788
52. Klevay MJ, Horn DL, Neofytos D, et al. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009; 64 (2): 152-157
53. Labelle AJ, Micek ST, Roubinian N, et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36 (11): 2967-2972
54. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118 (1): 146-155
55. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31 (12): 2742-2751
56. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31
57. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49 (8): 3171-3177
58. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51 (1): 35-39
59. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008; 52 (9): 3022-3028
60. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluco-nazole to the therapeutic response of patients with mu-cosal candidiasis and candidemia. Antimicrob Agents Chemother 2007; 51 (10): 3599-3604
61. Meyer M-H, Letscher-Bru V, Jaulhac B, et al. Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 2004; 42 (2): 773-777
62. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46 (7): 2222-2226
63. Lau A, Sorrell TC, Chen S, et al. Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol 2008; 46 (9): 3021-3027
64. Shepard JR, Addison RM, Alexander BD, et al. Multi-center evaluation of the Candida albicans/Candida glab-rata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008; 46: 50-55
65. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39 (2): 199-205
66. Obayashi T, Toshida M, Mori T, et al. Plasma (1-3)-b-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20
67. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41 (5): 654-659
68. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46 (6): 878-885
69. Persat F, Ranque S, Derouin F, et al. Contribution of the (1-3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46 (3): 1009-1013
70. Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1-3)-beta-D-glucan assay for the diagnosis of invasive fungal infections: a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46 (12): 1864-1870
71. Digby J, Kalbfleisch J, Glenn A, et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10 (5): 882-885
72. Pickering JW, Sant HW, Bowles CAP, et al. Evaluation of a (1-3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43 (12): 5957-5962
73. Machetti M, Furfaro E, Viscoli C. Non glucan-free plastic tubes for blood collection: effect on (1,3)-B-D-glucan detection [abstract]. Proceedings of the Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
74. Sendid B, Tabouret M, Poirot JL, et al. New enzyme im-munoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999; 37 (5): 1510-1517
75. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008; 46 (6): 890-896
76. Louie RF, Tang Z, Albertson TE, et al. Multiplex polymerase chain reaction detection enhancement of bac-teremia and fungemia. Crit Care Med 2008; 36(5): 1487-1492
77. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994; 331 (20): 1325-1330
78. Phillips P, Shafran S, Garber G, et al. Multicenter ran-domized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients: Canadian Candidemia Study Group. Eur J Clin Micro-biol Infect Dis 1997; 16 (5): 337-345
79. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Manage-ment of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23 (5): 964-972
80. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole ver-sus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366 (9495): 1435-1442
81. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347 (25): 2020-2029
82. Kuse E-R, Chetchotisakd P, da Cunha CA, et al. Mica-fungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369 (9572): 1519-1527
83. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356 (24): 2472-2482
84. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45 (7): 883-893
85. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36 (10): 1221-1228
86. Anaissie EJ, White M, Uzon O, et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial [abstract no. LM21]. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco (CA)
87. Mills EJ, Perri D, Cooper C, et al. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis [published erratum appears in Ann Clin Microbiol Antimicrob 2009; 8]. Ann Clin Microbiol Antimicrob 2009; 8: 23
88. Garey KW, Neuhauser MM, Bearden DT, et al. Evalua-tion of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006; 49 (3): 226-231
89. Meyer E, Schwab F, Gastmeier P, et al. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60 (3): 619-624
90. Bennett JE. Echinocandins for candidemia in adults with-out neutropenia. N Engl J Med 2006; 355 (11): 1154-1159
91. Sobel JD, Revankar SG. Echinocandins: first choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356 (24): 2525-2526
92. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro suscepti-bility of invasive isolates of Candida spp. to anidula-fungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-156
93. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10 (3): 121-130
94. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and mica-fungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46 (8): 2620-2629
95. Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect 2008; 14 Suppl. 4: 65-70
96. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flu-cytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24 (6): 426-432
97. Pappas PG, Kauffman CA, Andes D, et al. Clinical prac-tice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5): 503-535
98. Thursky KA, Playford EG, Seymour JF, et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38 (6b): 496-520
99. Shorr AF, Lazarus DR, Sherner JH, et al. Do clinical fea-tures allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007; 35 (4): 1077-1083
100. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36: 1993-1998
101. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49 (11): 4555-4560
102. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in non-neutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36 (7): 2034-2039
103. Lee I, Fishman NO, Zaoutis TE, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009; 169 (4): 379-383
104. Tumbarello M, Sanguinetti M, Trecarichi EM, et al. Fun-gaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 2008; 62 (6): 1379-1385
105. Louie A, Liu QF, Drusano GL, et al. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother 1998; 42 (6): 1512-1514
106. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. J Clin Microbiol 2006; 19: 435-447
107. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49 (1): 1-16
108. Bergner R, Hoffmann M, Riedel K-D, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006; 21 (4): 1019-1023
109. Muhl E, Martens T, Iven H, et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of flu-conazole. Eur J Clin Pharmacol 2000; 56 (9-10): 671-678
110. Hope WW, Billaud EM, Lestner J, et al. Therapeutic monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-586
111. Gumbo T. Impact of pharmacodynamics and pharmaco-kinetics on echinocandin dosing strategies. Curr Opin Infect Dis 2007; 20 (6): 587-591
112. Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48 (12): 1676-1684
113. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20 (3): 679-697
114. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Eva-luation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006; 50: 1587-1592
115. Oude Lashof AML, Donnelly JP, Meis JFGM, et al. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003; 22 (1): 43-48
116. Bross J, Talbot GH, Maislin G, et al. Risk factors for no-socomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87 (6): 614-620
117. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33 (2): 177-186
118. McKinnon PS, Goff DA, Kern JW, et al. Temporal as-sessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136 (12): 1401-8; discussion 9
119. Anaissie EJ, Rex JH, Uzun O, et al. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104 (3): 238-245
120. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34 (5): 591-599
121. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998; 19 (11): 846-850
122. Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and can-didemia [published erratum appears in Clin Infect Dis 2004 Oct 15; 39 (8): 1264]. Clin Infect Dis 2004; 38 (8): 1119-1127
123. Rex JH, Bennett JE, Sugar AM, et al. Intravascular ca-theter exchange and duration of candidemia. Clin Infect Dis 1995; 21 (4): 994-996
124. Rodriguez D, Park BJ, Almirante B, et al. Impact of early central venous catheter removalonoutcome inpatients with candidaemia. Clin Microbiol Infect 2007; 13 (8): 788-793
125. Pasqualotto AC, Severo LC. The importance of central venous catheter removal in patients with candidaemia: time to rethink our practice? Clin Microbiol Infect 2008; 14 (1): 2-4
126. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 34: 600-602
127. Bennett JE. Echinocandins for candidemia in adults with-out neutropenia. N Engl J Med 2006; 355 (11): 1154-1159
128. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989; 149 (10): 2226-2228
129. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20 (3): 485-506
130. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, et al. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine 2003; 82 (3): 187-202
131. Ables AZ, Blumer NA, Valainis GT, et al. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9 (4): 169-175
132. Eggimann P, Francioli P, Bille J, et al. Fluconazole pro-phylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27 (6): 1066-1072
133. Garbino J, Lew DP, Romand J-A, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717
134. He YM, Lv XS, Ai ZL, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 2003; 9 (11): 2619-2621
135. Jacobs S, Price Evans DA, Tariq M, et al. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Critical Care Med 2003; 31 (7): 1938-1946
136. Parizkova R, Cerny V, Dostal P, et al. The effect of pro-phylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a Neodkladna Pece 2000; 11 (6): 271-275
137. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candi-dal infections in critically ill surgical patients. Ann Surg 2001; 233 (4): 542-548
138. Sandven P, Qvist H, Skovlund E, et al., the Norwegian Yeast Study G. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Critical Care Med 2002; 30 (3): 541-547
139. Shorr AF, Chung K, Jackson WL, et al. Fluconazole pro-phylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33 (9): 1928-35; quiz 36
140. Playford EG, Webster AC, Sorrell TC, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically-ill and surgical patients: systematic review and meta-analysis of randomised clinical trials. J Antimicrob Chemother 2006; 57: 628-638
141. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005; 31 (11): 1479-1487
142. Ho KM, Lipman J, Dobb GJ, et al. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care 2005; 9: R710-7
143. Vardakas KZ, Samonis G, Michalopoulos A, et al. Anti-fungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34 (4): 1216-1224
144. Ostrosky-Zeichner L, Pappas P, Shoham S, et al. Re-validation and improvement of a clinical prediction rule (CPR) for clinical trials on prophylaxis of invasive can-didiasis (IC) in the ICU [abstract]. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
145. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26 (4): 271-276
146. Paphitou NI, Ostrosky-Zeichner L, Rex J. Rules for iden-tifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systemic use in antifungal prophylaxis trials. Medical Mycol 2005; 43: 235-243
147. Leon C, Ruiz-Santana S, Saavedra S, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34 (3): 730-737
148. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220 (6): 751-758
149. Faiz S, Neale B, Rios E, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009; 28 (6): 689-692
150. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37 (5): 1624-1633
151. Playford EG, Lipman J, Kabir M, et al. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009; 35: 2141-2145
152. Ostrosky-Zeichner L. Issues in the design and interpreta-tion of antifungal drug trials in the critically ill. Curr Opin Infect Dis 2009; 22 (6): 564-567
153. Normand S, Francois B, Darde M-L, et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Med 2005; 31 (11): 1508-1513
154. Eggimann P, Wolff M, Garbino J. Oral nystatin as anti-fungal prophylaxis in critically ill patients: an old SDD tool to be renewed? Intensive Care Med 2005; 31 (11): 1466-1468
155. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32 (12): 2443-2449
156. Leon C, Alvarez-Lerma F, Ruiz-Santana S, et al. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis 2009; 28 (3): 233-242
157. Magill SS, Swoboda SM, Johnson EA, et al. The associa-tion between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients [published erratum appears in Diagn Microbiol Infect Dis 2007 Mar; 57 (3): 351]. Diagn Microbiol Infect Dis 2006; 55 (4): 293-301
158. Toya SP, Schraufnagel DE, Tzelepis GE. Candiduria in intensive care units: association with heavy colonization and candidaemia. J Hosp Infect 2007; 66 (3): 201-206
159. Perez-Parra A, Munoz P, Guinea J, et al. Is Candida colo-nization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? Intensive Care Med 2009; 35 (4): 707-712
160. Hollenbach E. To treat or not to treat: critically ill patients with candiduria. Mycoses 2008; 51 Suppl. 2: 12-24
161. Delisle M-S, Williamson DR, Perreault MM, et al. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008; 23 (1): 11-17
162. Eggimann P, Lamoth F, Marchetti O. On track to limit antifungal overuse! Intensive Care Med 2009; 35 (4): 582-584
163. Takesue Y, Kakehashi M, Ohge H, et al. Combined as-sessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004; 28 (6): 625-630
164. Schuster MG, Edwards Jr JE, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149 (2): 83-90
165. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients. Part II: treatment. Intensive Care Med 2009; 35 (2): 206-214
166. Spellberg BJ, Filler SG, Edwards Jr JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42 (1): 244-251